Post Profile






New data on PM1183 sees a response rate of 36 percent as single agent in patients with SCLC

(Pharmamar) Up to today, there is only one approved therapy, topotecan, in relapsed disease, that offers a response rate of between 17 percent and 24 percent.
read more

share

Related Posts


High Response Rates, Long-Term Remissions Seen in Penn Trials of Personalized Cellular Therapy CTL019 for Pediatric and Adult Blood Cancers

Health : Newswise Medical News

Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous remis...

Improved Survival Shown in Early-Stage Hodgkin's Disease Patients Who Receive Radiation Therapy

Health : Newswise Medical News

Patients with stage I and II Hodgkin's Disease who receive consolidated radiation therapy (RT) have a higher 10-year survival rate of 84 percent, compared to 76 percent for patients who did not receive RT; and, the data also shows a...

PharmaMar Announces The Initiation Of Phase I Clinical Trials With PM1183, A New Antitumor Compound

Health : Medical News Today

PharmaMar SA (Grupo Zeltia, ZEL.MC) announces the initiation of Phase I clinical trials with PM1183, a new antitumor compound developed by PharmaMar's internal research program. The first patient enrolled in the trial has already st...

PharmaMar completes the patient recruitment for the Phase 3 pivotal study with PM1183

Health : EurekAlert: Health

(Pharmamar) PharmaMar announces today that the patient recruitment for the randomized and pivotal Phase III 'CORAIL' study with lurbinectedin (PM1183), for the treatment of platinum-resistant ovarian cancer, has been successfully co...

PharmaMar announces positive results from its Phase 2 study with PM1183 in BRCA 1/2 MBC

Health : EurekAlert: Health

(Pharmamar) The data was presented at an oral session at the European Society of Medical Oncology.The study meets its primary objective obtaining an overall response rate (ORR) in 41 percent of the patients. In the BRCA 2 subgroup, ...

Comments


Copyright © 2016 Regator, LLC